OMEICOS Therapeutics
Latest round
- Series C
Last raised
- Nov 2018
Total raised
- $35M
Investors
- 11
About OMEICOS Therapeutics
Founded in 2013 in Berlin, Germany, OMEICOS Therapeutics GmbH specializes in therapeutic advancements.500 mn from the Federal Ministry of Education and Research.OMEICOS Therapeutics specializes in developing therapies targeting cardiovascular, inflammatory, and mitochondrial diseases, particularly with its lead product, OMT-28. This product has shown efficacy in clinical trials, especially in a Phase 2 study for patients with atrial fibrillation, demonstrating a strong safety profile and notable impacts on biomarkers like GDF-15 and IL-6. The company is currently progressing OMT-28 through further testing in a Phase II proof-of-concept study for myopathy and cardiomyopathy in individuals with primary mitochondrial diseases.OMEICOS Therapeutics generates revenue through partnerships and clinical collaborations, engaging predominantly in B2B transactions with healthcare institutions and clinical trial sponsors. As OMT-28 advances through clinical trials, the company may seek further commercialization agreements, potentially involving licensing deals or joint ventures with pharmaceutical companies focused on cardiovascular treatments. The company aims to expand its market presence in Europe and North America, with specific initiatives planned for the next two years.
Who invested in OMEICOS Therapeutics
11 investors across 5 rounds
See all investors in OMEICOS Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about OMEICOS Therapeutics
Who invested in OMEICOS Therapeutics?
OMEICOS Therapeutics has 11 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has OMEICOS Therapeutics raised?
OMEICOS Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did OMEICOS Therapeutics last raise money?
OMEICOS Therapeutics's most recent round on record is a Series C, in Nov 2018.
What does OMEICOS Therapeutics do?
Founded in 2013 in Berlin, Germany, OMEICOS Therapeutics GmbH specializes in therapeutic advancements.
Where is OMEICOS Therapeutics headquartered?
OMEICOS Therapeutics is headquartered in Berlin, Germany.
Which VCs invest in companies like OMEICOS Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at OMEICOS Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like OMEICOS Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.